Clinical Trial ResultsMineralys announced positive topline results from the Phase II Explore-CKD study.
Market PotentialThe size of the market is significant, with a projection of over $5 billion as a large percentage of hypertensive patients do not have their systolic blood pressure under control.
Therapeutic RelevanceThe consistent lorundrostat data supports a robust forthcoming NDA submission, underscoring its therapeutic relevance in hypertension and related comorbid conditions.